China’s Fosun Pharma secured $3.3 million from Japan’s GHIT Fund to advance a triple artemisinin combination drug for malaria treatment. This formulation comprises artemether, lumefantrine, and amodiaquine in fixed doses. The funding will support the Phase III trial, a joint effort by Fosun, Marubini, MORU in Thailand, and MMV. Malaria, caused by plasmodium falciparum and transmitted by Anopheles mosquitoes, led to 249 million cases and 608,000 deaths last year, primarily in tropical areas, notably Africa where under-five-year-olds accounted for 78% of fatalities. The drug targets partial artemisinin resistance observed in the Greater Mekong Subregion, aiming to combat this issue and develop a child-friendly version due to the disease’s prevalence among children.
Global News and Digital Insights
for the Healthcare Industry
Menu
